The International Osteoporosis Foundation (IOF)
Storys aus Nyon, Switzerland
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
The International Osteoporosis Foundation (IOF)
Action for bone health is needed now more than ever, urges IOF
mehrCOVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them
Nyon, Switzerland (ots/PRNewswire) - New campaign, Let's treat it right, launches as online searches for self-care surge globally[1], as people take more responsibility for their everyday health. Today sees the launch of Let's treat it right, a major new health education campaign designed to bridge a knowledge gap ...
mehrThe International Osteoporosis Foundation (IOF)
Survey shows 90% of adults unaware of men's risk for osteoporosis
Nyon, Switzerland (ots) - Osteoporosis can lead to painful fractures, disability and early death, but continues to be ignored by the general public and neglected by doctors during routine physical check-ups New survey findings released on World Osteoporosis Day by the International Osteoporosis Foundation (IOF), show that on average, 90% of 13,258 adults questioned are unaware of how common osteoporotic fractures are in ...
mehrThe International Osteoporosis Foundation (IOF)
Woman at serious risk for osteoporosis and life-threatening fractures
Nyon, Switzerland (ots) - On World Osteoporosis Day, October 20, the International Osteoporosis Foundation (IOF) is calling for women to take action now to protect their bone health. Broken bones due to osteoporosis often result in pain, immobility and loss of quality of life as well as early death. In women over 45 years of age, osteoporosis accounts for more days ...
mehrShire Pharmaceuticals Group Plc
Positive Response from European Regulatory Procedure Supports Approval of Elvanse® (lisdexamfetamine dimesylate) for ADHD
Nyon, Switzerland (ots/PRNewswire) - Shire plc today announces a positive outcome from the European Decentralised Procedure (DCP) for Elvanse(R) (to be known as Tyvense(R) in Ireland). Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children ...
mehrShire Pharmaceuticals Group Plc
Shire Enters into Novel Research Collaboration with Italian-based Telethon's Institute of Genetics and Medicine for Rare Diseases
Nyon, Switzerland (ots/PRNewswire) - Shire plc , today announced a long-term, broad based, multi-indication research collaboration in rare diseases with Fondazione Telethon, a major Italian biomedical charitable foundation, for research carried out at the Telethon Institute of Genetics and Medicine (TIGEM). This ...
mehrThe International Osteoporosis Foundation (IOF)
Had a wrist fracture? Over 50? Get tested for osteoporosis / On World Osteoporosis Day the IOF warns that fragility fractures in adults should trigger testing for osteoporosis
Nyon, Switzerland (ots) - "A wrist fracture is a warning sign," says Professor John A. Kanis, president of the International Osteoporosis Foundation (IOF). "We urge all adults aged 50 and over who have suffered a wrist or other fragility fracture, to get tested for osteoporosis." Osteoporosis is a chronic 'silent' ...
mehrShire Pharmaceuticals Group Plc
Shire's VPRIV® (velaglucerase alfa for injection) Shows Significant Improvement in Gaucher-Related Bone Disease
Nyon, Switzerland (ots/PRNewswire) - - In a head-to-head trial between VPRIV and Cerezyme(R) (imiglucerase), only patients treated with VPRIV experienced statistically significant improvement in lumbar spine bone mineral density at 9 months Shire plc , the global specialty biopharmaceutical company, today presented ...
mehrShire Pharmaceuticals Group Plc
Phase 3 Study Shows Efficacy is Maintained With lisdexamfetamine dimesylate (LDX) in Children and Adolescents With ADHD After at Least 6 Months of Treatment
Nyon, Switzerland (ots/PRNewswire) - Significantly lower proportion of subjects experiencing treatment failure whilst receiving LDX in the randomised withdrawal period, compared to those subjects receiving placebo.[1] Today, at the EUNETHYDIS 2nd International ADHD Conference, Shire AG , the global specialty ...
mehrShire Pharmaceuticals Group Plc
More Choice for CKD Patients in Europe as FOSRENOL® is Approved in a New Oral Powder Formulation
Nyon, Switzerland (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, today announced it has received approval through the European Decentralised Procedure for an oral powder formulation of FOSRENOL (lanthanum carbonate). FOSRENOL is a non-calcium, non-resin phosphate binder indicated as a phosphate binding agent for use in the control of ...
mehrThe International Osteoporosis Foundation (IOF)
Three Steps to Unbreakable Bones on World Osteoporosis Day
Nyon, Switzerland (ots) - For this year's World Osteoporosis Day (October 20), the International Osteoporosis Foundation (IOF) is releasing a 24-page report promoting a three-step strategy for healthy bones and strong muscles. To view the Multimedia News Release (MNR), please click: http://multivu.prnewswire.com/mnr/prne/iof/52143/ Professor Heike Bischoff-Ferrari, director Centre on Aging and Mobility at the University ...
mehr